Skip to search formSkip to main contentSkip to account menu

NB 506

Known as: NB-506 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Antineoplastic AgentsCarbazolesEnzyme InhibitorsGlucosides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy.
Human DNA topoisomerase I is the target of camptothecins, which have been recently introduced in the clinic for cancer… 
Highly Cited
2001
Highly Cited
2001
Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
NB-506 is a topoisomerase I (top1) inhibitor in clinical trials. In this study, we used a series of camptothecin (CPT)-resistant… 
2001
2001
DNA binding properties of the indolocarbazole antitumor drug NB-506.
Indolocarbazoles derived from the antibiotic rebeccamycin represent an important group of antitumor agents. Several… 
1999
1999
The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor.
K-252b, a member of the staurosporine family of protein kinase inhibitors, selectively potentiates the activation of the nerve… 
Highly Cited
1999
Highly Cited
1999
Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
J-107088 [6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a… 
1999
1999
Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
The antitumor drug NB-506, which is currently undergoing phase I/II clinical trials, contains a DNA-intercalating indolocarbazole… 
Highly Cited
1996
Highly Cited
1996
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Topoisomerase I-targeting anticancer agents such as 7-ethyl-10-[4-(1-piperidyl)-1-piperidyl]carbonyloxy-camptothecin (CPT-11) and… 
Highly Cited
1995
Highly Cited
1995
Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor…
NB-506 [6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D- glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H… 
1995
1995
Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
The novel anticancer glucosyl derivative of indolo-carbazole (NB-506), an inhibitor of DNA topoisomerase I, exhibited strong in… 
Highly Cited
1995
Highly Cited
1995
Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of…
A new indolocarbazole antitumor agent, NB-506 [6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl) -5H… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)